Residual lung abnormalities were consistent with elevated epithelial injury biomarkers, profibrotic signaling.

Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

Abnormally high levels of lung-injury biomarkers in the blood after COVID-19 infection may flag patients at risk for ongoing lung disease, an Imperial College London–led study suggests.